Gene · 6041
RNASEL: ribonuclease L
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RNASEL: ribonuclease L. Genes, record 6041. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6041
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q05823 | 2-5A-dependent ribonuclease | 741 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents44
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026148146 A1 | 2026-07-09 | 30 | Q05823 | Espacenet |
| JP 2026094314 A | 2026-06-09 | 88 | Q05823 | Espacenet |
| JP 2026021360 A | 2026-02-10 | 130 | Q05823 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61867 | Q05823 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61868 | Q05823 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8250 | Q05823 | Espacenet |
| WO 2025217591 A1 | 2025-10-16 | 86 | Q05823 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8250 | Q05823 | Espacenet |
| JP 2025041709 A | 2025-03-26 | 111 | Q05823 | Espacenet |
| EP 4518908 A2 | 2025-03-12 | 6 | Q05823 | Espacenet |
1 to 10 of 44
See all 44 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,143
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RNASEL papers | Newest fiscal year |
|---|---|---|---|
| R01AI140442 | Betacoronaviruses: activation and antagonism of host innate immune responses | 15 | 2025 |
| R01CA249180 | Targeted degradation of RNAs by using small molecules | 12 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 9 | 2025 |
| R35NS116846 | Design of Precision Small Molecules Targeting RNA Repeating Transcripts to Manipulate and Study Disease Biology | 9 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 7 | 2025 |
| R01AI169537 | Human coronavirus infection of the nasal epithelium | 7 | 2025 |
| R01CA136367 | Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated Herpesvirus | 7 | 2025 |
| R35GM151249 | Understanding the OAS/RNase L pathway during pathogenic viral infections | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 6 | 2025 |
1 to 10 of 2,143Source NIH's project files
See all 2,143 nih grantsPapers3,466
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interferon-stimulated restriction factors in enterovirus infection: A review on the mechanisms and antiviral roles of shiftless (C19orf66). | Virology | 2027 | 42784970 | PubTator, text mining | PubMed |
| Benzothiazole derivatives target oligoadenylate synthetase and enhance RSV vaccine efficacy as adjuvants. | Bioact Mater | 2027 | 42592354 | PubTator, text mining | PubMed |
| Tumour-associated dsRNA accumulation and innate immune activation: mechanistic basis and therapeutic strategies. | EBioMedicine | 2026 | 42800308 | PubTator, text mining | PubMed |
| West African Clade C MERS-CoV Strains BF785 and Mor213 Induce More Robust Interferon and Inflammatory Signaling Compared to Clade A in Human Respiratory Cells. | Viruses | 2026 | 42797768 | PubTator, text mining | PubMed |
| Enterovirus RNase L inhibiting RNAs are highly conserved with limited phylogenetic distribution. | RNA | 2026 | 42772853 | PubTator, text mining | PubMed |
| Linker Optimization of cMYC RIBOTAC for Efficient cMYC Modulation. | ChemMedChem | 2026 | 42745536 | PubTator, text mining | PubMed |
| Association of selected ELAC2, MSR1, RNASEL and KLK3 polymorphisms with prostate cancer susceptibility in a Hungarian cohort. | Pathol Oncol Res | 2026 | 42729212 | PubTator, text mining | PubMed |
| Systemic removal of host restriction factors enables rapid, scalable virus production for cell culture-based vaccine development. | Front Bioeng Biotechnol | 2026 | 42698639 | PubTator, text mining | PubMed |
| RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis. | Sci Adv | 2026 | 42647607 | PubTator, text mining | PubMed |
| Tumour-Derived Extracellular Vesicles Containing dsRNA Induce Degradation of Ribosomal Protein mRNA in Platelets. | J Extracell Vesicles | 2026 | 42572919 | PubTator, text mining | PubMed |
1 to 10 of 3,466
See all 3,466 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6041
GET https://conductscience.org/api/genes/v1/6041/patents?page=2